InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904


JENA, Germany, Dec. 20, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the first patient has been dosed in its Phase 2a basket study in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS), investigating the Company’s oral C5aR inhibitor, INF904.

Read the rest here:
InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904

Related Posts